SCHEMBL5730488

SCHEMBL5730488

COc1ccc(-c2c(C)n[nH]c2N)c(OC)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
MAPK1 P28482 2/20 0.57
GAA P10253 1/20 0.57
HTT P42858 1/20 0.57
GFER P55789 1/20 0.57
KDM4E B2RXH2 4/20 0.52
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
HPGD P15428 1/20 0.48
ALPL P05186 1/20 0.46
ILK Q13418 2/20 0.45
CYP1A1 P04798 3/20 0.44
CYP1B1 Q16678 3/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
ALOX12 P18054 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CYP3A4 P08684 2/20 0.44
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2402669 0.87 DRD1 (0.47) ALDH1A1MAPK1GAAHTTGFER
SCHEMBL14491026 0.85 ALDH1A1 (0.42) ALDH1A1MAPK1GAAHTTGFER
SCHEMBL1868350 0.84 HSP90AA1 (0.48) ALDH1A1MAPK1GAAHTTGFER
SCHEMBL14350130 0.84 GAA (0.45) ALDH1A1MAPK1GAAHTTGFER
SCHEMBL13516427 0.80 MAPT (0.50) ALDH1A1MAPK1GAAGFERKDM4E
SCHEMBL5730709 0.76 GAA (0.39) ALDH1A1MAPK1GAAHTTGFER
SCHEMBL4863136 0.76 KDM4E (0.64) ALDH1A1MAPK1GAAKDM4EMEN1
SCHEMBL13310497 0.75 CCNT1 (0.42) ALDH1A1MAPK1GAAHTTGFER
SCHEMBL686489 0.74 ILK (0.72) ILK
SCHEMBL14502125 0.74 ALDH1A1 (0.33) ALDH1A1MAPK1GAAHTTGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070129382-A1 Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses SB PHARMCO PUERTO RICO (PR) 2007-06-07 US disclosed
US-20070129382-A1 Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses SB PHARMCO PUERTO RICO (PR) 2007-06-07 US disclosed
EP-1218381-B1 AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES NEUROGEN CORP (US) 2006-12-06 EP disclosed
US-6476038-B1 Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines NEUROGEN CORPORATION 2002-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129382-A1 Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses CRH, CRHR1, CRHR2 ALDH1A1 2863/4885MAPK1 3347/4885GAA 1150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.